ArticleJournal of intensive care medicine2020
Current Status of Novel Biomarkers for the Diagnosis of Acute Kidney Injury: A Historical Perspective.
Article in Journal of intensive care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review.PloS one · 2025Pooled it
- The evolving field of nephrology: what comes next? A report from the European Renal Association Scientific Advisory Board.Clinical kidney journal · 2026Review
- Risk of Rhabdomyolysis and Kidney Injury after Intensive Exercise. Potential of Novel Biomarkers of Kidney Injury: A Narrative Review.Journal of human kinetics · 2026Review
- Acute Kidney Injury Biomarkers in Perioperative Care: A Scoping Review of Clinical Implementation.Diagnostics (Basel, Switzerland) · 2025Review
- Clinical, immune and genetic risk factors of malaria-associated acute kidney injury in Zambian children: A study protocol.PloS one · 2025Observational
- Sepsis-Associated Acute Kidney Injury in Critically Ill Children: Incidence and Outcomes.Journal of clinical medicine · 2024Article
- Article
- A modified renal angina index in critically ill patients with COVID-19.Renal failure · 2023Article
- Prediction of urinary dickkopf-3 for AKI, sepsis-associated AKI, and PICU mortality in children.Pediatric research · 2023Article
- Trimethylamine, a gut bacteria metabolite and air pollutant, increases blood pressure and markers of kidney damage including proteinuria and KIM-1 in rats.Journal of translational medicine · 2022Article
- Assessing the value of serum and urinary interleukins for diagnosis of acute kidney injury in children and adolescents: A systematic review and meta-analysis.Practical laboratory medicine · 2022Review
- Prediction models for acute kidney injury in critically ill patients: a protocol for systematic review and critical appraisal.BMJ open · 2021Article
- MicroRNAs in toxic acute kidney injury: Systematic scoping review of the current status.Pharmacology research & perspectives · 2021Article
- Epoxyeicosatrienoic Acid Analog and 20-HETE Antagonist Combination Prevent Hypertension Development in Spontaneously Hypertensive Rats.Frontiers in pharmacology · 2021Article
- Acute Kidney Injury: Diagnosis and Management.Indian journal of pediatrics · 2020Review
- SuPAR: a potential predictive biomarker for acute kidney injury.Nature reviews. Nephrology · 2020Article
- Biomarkers in Acute Kidney Injury.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2020Review
- Analysis of Spatiotemporal Urine Protein Dynamics to Identify New Biomarkers for Sepsis-Induced Acute Kidney Injury.Frontiers in physiology · 2020Article
- Renal glycosuria as a novel early sign of colistin-induced kidney damage in mice.Antimicrobial agents and chemotherapy · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Acute kidney injury (AKI) is a common and serious medical condition associated with significant increases in morbidity, mortality, and cost of care. Because of the high incidence and poor outcomes associated with AKI, there has been significant interest in the development of new therapies for the prevention and treatment of the disease. A lack of efficacy in drug trials led to the concern that AKI was not being diagnosed early enough for an effective intervention and that a rise in serum creatinine itself is not a sensitive-enough marker. Researchers have been searching for novel biomarkers that can not only assess a decline in kidney function but also demonstrate structural damage to the kidney and at time points earlier than increases in serum creatinine measurements allow. Over the past 10 years, there have been 3300 new publications and hundreds of new biomarkers investigated, yet concern still remains regarding AKI biomarker performance. The AKI biomarkers are yet to be widely utilized in clinical practice, leading some to question whether AKI biomarkers will ever reach their initial promise. However, we believe that biomarkers are an important part of current and future AKI research and clinical management. In this review, we compare the historical contexts of acute myocardial ischemia and AKI biomarker development to illustrate the progress that has been made within AKI biomarker research in a relatively short period of time and also to point out key differences between the disease processes that have been barriers to widespread AKI biomarker adoption. Finally, we discuss potential paths by which biomarkers can lead to appropriate AKI treatment responses that lower morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.